Clinical Outcome of Vinpocetine in Diabetic Nephropathy
Status:
RECRUITING
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The goal of this controlled, randomized, clinical trial is to evaluate the effect of vinpocetine on clinical outcomes on the diabetic nephropathy patients.
The following will be evaluated; anthropometrics, kidney functions, glucose panel, lipid panel, ICAM-1, quality of life.
Participants will receive either vinpocetine or placebo, twice daily for 3 months.